Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Fineline Cube Feb 27, 2026
Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Fineline Cube Feb 27, 2026
Company Drug

CORXEL’s Varenicline Nasal Spray Approved by NMPA for Dry Eye Treatment

Fineline Cube Nov 27, 2024

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has received approval...

Company Deals

Arrowhead and Sarepta Seal $11.38 Billion Global Licensing Deal for Rare Disease Treatments

Fineline Cube Nov 27, 2024

US-based companies Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) and Sarepta Therapeutics (NASDAQ: SRPT) have announced a...

Company Drug

Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China

Fineline Cube Nov 27, 2024

US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a strategic agreement with China...

Legal / IP

Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035

Fineline Cube Nov 27, 2024

The China National Intellectual Property Administration (CNIPA) has granted Swiss pharmaceutical giant Roche (SWX: ROG)...

Company Drug

CanSino Biologics’ Menhycia Vaccine Aims to Expand Age Range with NMPA Filing

Fineline Cube Nov 27, 2024

CanSino Biologics (HKG: 6185) has announced that the National Medical Products Administration (NMPA) has accepted...

Company Drug

Jiangsu Hengrui Medicine’s SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial

Fineline Cube Nov 27, 2024

Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received clinical trial...

Company Drug

AstraZeneca’s Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study

Fineline Cube Nov 27, 2024

UK-based pharmaceutical giant AstraZeneca Inc., (AZ, NASDAQ: AZN) has announced that its Phase III CAPItello-281...

Company Drug

Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA

Fineline Cube Nov 27, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Drug

J&J’s Stelara Faces New Biosimilar Competition in China with CSPC Pharmaceutical’s Entry

Fineline Cube Nov 27, 2024

Johnson & Johnson (J&J, NYSE: JNJ)’s auto-immune disease drug Stelara (ustekinumab) is set to encounter...

Company Deals Policy / Regulatory

AstraZeneca’s ALXN1850 (Efzimfotase Alfa) Selected for China’s Rare Disease Care Plan

Fineline Cube Nov 27, 2024

The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s...

Company Drug

Amgen’s MariTide Showcases Significant Weight Loss in Phase II Study

Fineline Cube Nov 27, 2024

US biotechnology company Amgen (NASDAQ: AMGN) has announced positive outcomes from the double-blind, dose-ranging Phase...

Company Deals

VectorBuilder and Zhejiang Dapu Biotechnology Form Partnership to Advance Biotech Innovation

Fineline Cube Nov 27, 2024

China-based gene delivery technology developer VectorBuilder has entered into a partnership with Zhejiang Dapu Biotechnology...

Company Drug

Roche’s SKYSCRAPER-01 Study: Tiragolumab-Tecentriq Combo Misses Primary Endpoint in NSCLC

Fineline Cube Nov 27, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has reported an update on the phase III SKYSCRAPER-01...

Company Deals

Roche to Acquire Poseida Therapeutics in a USD 1.5 Billion Deal

Fineline Cube Nov 26, 2024

US-based clinical-stage biopharmaceutical company, Poseida Therapeutics (NASDAQ: PSTX), which specializes in donor-derived CAR-T cell therapies,...

Company Medical Device

Zymeworks and Jazz Pharmaceuticals’ Ziihera Gets Green Light for HER2+ BTC Treatment

Fineline Cube Nov 26, 2024

Partners Zymeworks Inc. (NASDAQ: ZYME) and Jazz Pharmaceuticals, Inc. have received accelerated approval from the...

Company Deals

Lakeside Holding’s Hupan Pharmaceutical Partners with Sinopharm Group Hubei for Supply Chain Services

Fineline Cube Nov 26, 2024

US-based supply chain solution provider Lakeside Holding Limited (NASDAQ: LSH), which specializes in the Asian...

Policy / Regulatory

NHSA to Announce NRDL Adjustment Results at November 28th Press Conference

Fineline Cube Nov 26, 2024

The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price...

Policy / Regulatory

NMPA and Local Governments Streamline Drug Approval Processes in China

Fineline Cube Nov 26, 2024

The National Medical Products Administration (NMPA) has released a notification regarding the pilot work for...

Company Deals

Adcendo ApS Secures Oversubscribed USD135 Million Series B Financing to Advance ADC Pipeline

Fineline Cube Nov 26, 2024

Danish antibody drug conjugate (ADC) specialist, Adcendo ApS, has announced the completion of an oversubscribed...

Company Medical Device

Abbott Laboratories Expands Structural Heart Portfolio with TAVI Balloon-Expandable System

Fineline Cube Nov 26, 2024

US-based Abbott Laboratories (NYSE: ABT) has announced the successful application of its transcatheter aortic valve...

Posts pagination

1 … 220 221 222 … 627

Recent updates

  • Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars
  • Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion
  • Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry
  • Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate
  • Akeso’s Manfidokimab NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Company

Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion

Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.